
C-Path Appoints Health Outcomes Expert as Executive Director of the Rare Disease COA Consortium

Dr. Lindsey Murray will lead C-Path's New Rare Disease COA Consortium

TUCSON, Ariz., January 13, 2022 — [Critical Path Institute \(C-Path\)](#) today announced it has named Lindsey Murray, Ph.D., MPH, as Executive Director of its Rare Disease Clinical Outcome Assessment (COA) Consortium, effective immediately. Murray joined C-Path in 2019 as Associate Director for rare diseases within C-Path's Patient-Reported Outcome Consortium.



Lindsey Murray, Ph.D.

“Lindsey is a tremendous asset to C-Path and I’m grateful she joined the team to help establish the Rare Disease COA Consortium and, ultimately, become its founding Executive Director,” said Stephen Joel Coons, Ph.D., Senior Vice President for C-Path’s Clinical Outcome Assessment Program. “Her efforts, underwritten by grant funding from FDA, enabled us to launch a viable and sustainable multi-stakeholder consortium on January 1st aimed at facilitating the evaluation of new drugs and biologics for the treatment or cure of rare diseases. She has my full support in this exceptionally worthwhile endeavor.”

As executive director, Murray will provide scientific and operational leadership for this pre-competitive public-private partnership among C-Path, FDA, the National Organization for Rare Disorders (NORD), other governmental and non-governmental organizations, and key partners in the biopharma, clinical research and patient communities that are seeking and/or developing treatments

for rare diseases.

Murray’s experience extends for over 15 years in health outcomes research, specializing in quantifying the patient’s perspective of health, illness and treatment through COA development, psychometric testing and the design and analysis of clinical trials involving COAs. Prior to joining C-Path, Murray served as a research scientist and Director of the EXacerbations of Chronic Pulmonary Disease Tool (EXACT®) PROgram at Evidera.

“I’m honored to take on leadership of the Rare Disease COA Consortium,” said Murray. “We’ve brought together an amazing group of collaborators, including regulatory, clinical, outcomes research and patient advocacy experts. I’m looking forward to continuing to build out the Rare Disease COA Resource that will help guide patient-centered COA selection in rare disease medical product development, as well as collectively tackling the pressing methodological challenges faced in rare disease research programs.”

Murray holds a Ph.D. in epidemiology from George Washington University, where she also received her MPH in epidemiology with a certificate in health promotion. She has a BA from the University of Virginia in Charlottesville, Virginia, where she double majored in anthropology and biology with a minor in German literature and language studies.

For more information on C-Path’s Rare Disease COA Consortium, visit: c-path.org/programs/rd-coac.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling \$13,239,950, and 45.8% funded by non-government source(s), totaling \$11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit [FDA.gov](https://www.fda.gov).

Specific funding for the establishment of the Rare Disease COA Consortium was provided by FDA grant U01FD006882.



About C-Path

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

Contact:

Kissy Black
C-Path
615.310.1894
kblack@c-path.org